Intuitive Surgical, Inc.

NasdaqGS:ISRG Stock Report

Market Cap: US$191.7b

Intuitive Surgical Valuation

Is ISRG undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ISRG when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ISRG ($543.6) is trading above our estimate of fair value ($316.42)

Significantly Below Fair Value: ISRG is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ISRG?

Key metric: As ISRG is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for ISRG. This is calculated by dividing ISRG's market cap by their current earnings.
What is ISRG's PE Ratio?
PE Ratio86.3x
EarningsUS$2.24b
Market CapUS$191.66b

Price to Earnings Ratio vs Peers

How does ISRG's PE Ratio compare to its peers?

The above table shows the PE ratio for ISRG vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average43.4x
SYK Stryker
39.9x11.6%US$145.9b
ABT Abbott Laboratories
34.5x11.6%US$200.3b
BSX Boston Scientific
74.4x23.3%US$132.9b
MDT Medtronic
24.8x10.2%US$107.2b
ISRG Intuitive Surgical
86.3x11.5%US$191.7b

Price-To-Earnings vs Peers: ISRG is expensive based on its Price-To-Earnings Ratio (86.3x) compared to the peer average (43.4x).

Price to Earnings Ratio vs Industry

How does ISRG's PE Ratio compare vs other companies in the US Medical Equipment Industry?

4 CompaniesPrice / EarningsEstimated GrowthMarket Cap
BDMD Baird Medical Investment Holdings
4.7xn/aUS$62.97m
MHUA Meihua International Medical Technologies
1.6xn/aUS$15.47m
PAVM PAVmed
0.6x-90.0%US$9.34m
RTSL Rapid Therapeutic Science Laboratories
0.3xn/aUS$18.99k
No more companies available in this PE range
ISRG 86.3xIndustry Avg. 37.3xNo. of Companies7PE020406080100+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: ISRG is expensive based on its Price-To-Earnings Ratio (86.3x) compared to the US Medical Equipment industry average (37.3x).

Price to Earnings Ratio vs Fair Ratio

What is ISRG's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ISRG PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio86.3x
Fair PE Ratio40.5x

Price-To-Earnings vs Fair Ratio: ISRG is expensive based on its Price-To-Earnings Ratio (86.3x) compared to the estimated Fair Price-To-Earnings Ratio (40.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ISRG forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$543.60
US$547.43
+0.7%
13.8%US$650.00US$265.00n/a26
Dec ’25US$542.00
US$536.43
-1.0%
12.8%US$643.00US$265.00n/a26
Nov ’25US$506.34
US$529.70
+4.6%
12.0%US$604.00US$265.00n/a26
Oct ’25US$484.76
US$486.45
+0.3%
12.2%US$586.00US$265.00n/a26
Sep ’25US$492.63
US$482.03
-2.2%
12.4%US$586.00US$265.00n/a26
Aug ’25US$450.94
US$469.35
+4.1%
11.0%US$525.00US$265.00n/a25
Jul ’25US$436.24
US$426.49
-2.2%
11.2%US$500.00US$253.00n/a25
Jun ’25US$402.12
US$423.57
+5.3%
11.0%US$500.00US$253.00n/a25
May ’25US$371.70
US$420.59
+13.2%
10.5%US$475.00US$253.00n/a25
Apr ’25US$394.87
US$414.11
+4.9%
10.5%US$475.00US$253.00n/a25
Mar ’25US$397.90
US$408.45
+2.7%
12.1%US$475.00US$230.00n/a25
Feb ’25US$383.83
US$402.75
+4.9%
13.9%US$475.00US$230.00n/a25
Jan ’25US$337.36
US$337.19
-0.05%
13.2%US$400.00US$230.00n/a25
Dec ’24US$315.20
US$326.63
+3.6%
12.7%US$400.00US$230.00US$542.0025
Nov ’24US$270.46
US$324.90
+20.1%
12.8%US$400.00US$230.00US$506.3424
Oct ’24US$292.29
US$361.91
+23.8%
10.5%US$400.00US$230.00US$484.7623
Sep ’24US$310.41
US$361.91
+16.6%
10.5%US$400.00US$230.00US$492.6323
Aug ’24US$323.95
US$361.91
+11.7%
10.5%US$400.00US$230.00US$450.9423
Jul ’24US$341.94
US$310.48
-9.2%
10.5%US$365.00US$204.00US$436.2421
Jun ’24US$310.54
US$308.19
-0.8%
10.1%US$365.00US$204.00US$402.1221
May ’24US$303.02
US$305.24
+0.7%
9.6%US$350.00US$204.00US$371.7021
Apr ’24US$255.47
US$271.48
+6.3%
11.5%US$325.00US$204.00US$394.8721
Mar ’24US$227.33
US$273.80
+20.4%
12.3%US$325.00US$204.00US$397.9020
Feb ’24US$251.19
US$273.80
+9.0%
12.3%US$325.00US$204.00US$383.8320
Jan ’24US$265.35
US$271.05
+2.1%
14.7%US$325.00US$204.00US$337.3621
Dec ’23US$274.49
US$260.30
-5.2%
13.8%US$325.00US$204.00US$315.2020

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y